CareCost Prior authorization
Required
Check what the payer requires before you schedule Actemra.
Prior authorization · DMARD and biologic step therapy · covered dosing · site of care
29 payer policy sets · source-linked · reviewed August 2026
Aetna + Rheumatoid arthritis is shown as a live example until you choose a payer.
This payer requires an approval on file before Actemra is purchased or infused for this member.
Precertification of a tocilizumab product is required of all Aetna participating providers and members in applicable plan designs.
Covered under ICD-10 M05, M06.
For adult members who have previously received a biologic or targeted synthetic drug (e.g., Rinvoq, Xeljanz) indicated for moderately to severely active rheumatoid arthritis (RA)
What opens in CareCost
Aetna · Actemra · Rheumatoid arthritis
For every requirement: the exact payer criteria, the source citation, a check-off, and a save to the patient’s chart.
In CareCost: check off each requirement · save to the patient · print for the chart
Aetna · Actemra · Rheumatoid arthritis
You have already checked the policy, indication and covered dose. Open the remaining requirements and work them as a patient checklist.
CareCost tracks Actemra coverage requirements across 29 payer policy sets.
Aetna · Anthem / Elevance · UnitedHealthcare · Regence · Premera · BCBS plans + more
Coverage clearance is only the first step.
CareCost carries the same patient through the entire workflow.
Finish this patient’s estimate →27 of 29 commercial payers require prior authorization, across 673 rules. Clinical-prerequisite, step-therapy and reauthorization rules vary by plan and by indication.
27 require PA · 28 apply a clinical prerequisite · 17 restrict site of care · 13 of 29 name a preferred tocilizumab product
27 of the 29 payers in CareCost’s Actemra corpus require an approval on file before the drug is purchased or infused.
Six ICD-10 families are covered, one per intravenous label indication: rheumatoid arthritis (M06.9, 27 of 29 payers), polyarticular JIA (M08.00, 26), systemic JIA (M08.20, 25), giant cell arteritis (M31.6, 27), cytokine release syndrome (D89.83, 25) and hospitalized COVID-19 (U07.1, 12).
Clinical-prerequisite rules are the largest category in the corpus: 350 of 673, across 28 of 29 payers. For rheumatoid arthritis, most start with a conventional DMARD: Anthem requires “an inadequate response to methotrexate titrated to maximally tolerated dose.” Several payers require a TNF antagonist or a preferred infused biologic to fail first: BCBS Kansas and BCBS South Carolina require “TWO self-injectable TNF antagonists or oral Janus Kinase Inhibitor”; Independence requires “a documented failure, contraindication, or intolerance to infliximab (Remicade) or golimumab (Simponi Aria).” Giant cell arteritis starts with a corticosteroid: BCBS Florida requires “ONE systemic corticosteroid… for at least a 7-day duration of therapy.” Systemic JIA starts with NSAIDs or steroids: Horizon requires “NSAIDs… for at least 1 month.”
37 dosing rules converge on the label’s regimen. BCBS Arkansas states it directly: “Rheumatoid Arthritis - 4 mg/kg every four weeks followed by an increase to 8 mg/kg every 4 weeks based on clinical response. Doses exceeding 800 mg per infusion are not recommended.”
22 rules cap the dose or the course. BCBS Kansas: “the dose should not exceed 800 mg every 28 days.” BCBS Minnesota repeats the label’s 600 mg ceiling without naming an indication: “Doses exceeding 600 mg per infusion are not recommended.” Cytokine release syndrome is capped by course: BCBS Louisiana: “No more than 4 total doses of tocilizumab (Actemra).” Regence: “Up to 4 infusions… No additional doses will be authorized.”
Four payers document a renewal period, across 8 rules. Capital BlueCross: “Prior authorization validity may be renewed every 12 months (365 days) thereafter.” BCBS Michigan requires documented benefit at renewal: “current criteria are met and… the medication is providing clinical benefit.” Cytokine release syndrome is the exception — BCBS Michigan: “Not applicable as no further authorization will be provided.”
22 rules restrict where the infusion can happen. Aetna: “Site of Care Utilization Management Policy applies to intravenous tocilizumab products.” BCBS South Carolina: “may only be authorized to be administered in certain locations (sites of care), such as an infusion center or the patient’s h[ome].” Florida Blue refers to its own policy: “Refer to 09-J3000-46, Site of Care Policy for Select Non-Oncology Medications.” BCBS Tennessee treats hospitalized COVID-19 differently: “Hospitalized members receiving treatment for COVID-19 will be managed according to the member’s inpatient benefit.”
Actemra’s 29-payer corpus converges on the same shape before it pays: a conventional drug first, a stricter step at several payers, and a biosimilar steer that runs in both directions.
| Requirement | What the corpus documents | Basis |
|---|---|---|
| Conventional DMARD first | Methotrexate titrated to a maximally tolerated dose, or another synthetic DMARD, for rheumatoid arthritis and JIA | Clinical-prerequisite rules, 350 of 673, across 28 of 29 payers |
| TNF antagonist or infused biologic first | Two self-injectable TNF antagonists or an oral JAK inhibitor (BCBS Kansas, South Carolina) or a documented infliximab/Simponi Aria failure (Independence, Excellus, HMSA, Blue Shield CA) | Clinical-prerequisite quotes, below |
| Corticosteroid first | Giant cell arteritis: one systemic corticosteroid trial before Actemra | Clinical-prerequisite rules tagged giant cell arteritis, 22 of 29 payers |
| NSAID or steroid first | Systemic JIA: NSAIDs or systemic glucocorticoids before Actemra | Clinical-prerequisite rules tagged systemic JIA, 23 of 29 payers |
| Preferred tocilizumab product | Tyenne preferred over branded Actemra (Independence, Wellmark, BCBS Nebraska); Actemra itself preferred (BCBS Arkansas, BCBS South Carolina) | Preferred-product rules, 13 of 29 payers |
Actemra is a standard Medicare Part B buy-and-bill drug, priced off the ASP-based fee schedule under J3262 for the FDA-labeled indications below; see the cost estimate for the current rate and the 20% coinsurance after the Part B deductible. It carries no national coverage determination or registry requirement: a covered diagnosis, medical necessity, and a claim coded to the indication treated. COVID-19 is a hospitalized indication and falls under the inpatient benefit, not this Part B claim.
It depends on the payer and plan. In CareCost’s Actemra corpus, 27 of 29 commercial payers require prior authorization, and step therapy against a conventional DMARD applies at nearly every one. Check this patient’s payer →
Most Actemra (J3262) policies start with the same core: a covered indication, a documented trial of a conventional DMARD such as methotrexate, and the covered dose. At many payers a TNF antagonist or a preferred infused biologic must fail first, and 13 of 29 name a preferred tocilizumab product. CareCost turns the applicable policy into a patient-level checklist, each item with the exact policy language behind it. Open patient clearance →
Yes. Original Medicare pays for Actemra under Part B as a physician-administered biologic, billed under J3262 and priced off the ASP-based fee schedule. See the cost estimate →
At 27 of 29 payers, yes. Most require a conventional DMARD trial, often methotrexate titrated to a maximally tolerated dose, before Actemra; BCBS Kansas and BCBS South Carolina require two self-injectable TNF antagonists or an oral JAK inhibitor, and Independence, Excellus, HMSA and Blue Shield of California require a documented infliximab or Simponi Aria failure. Thirteen of 29 payers also name a preferred tocilizumab product: Independence, Wellmark and BCBS Nebraska prefer the biosimilar Tyenne over branded Actemra, while BCBS Arkansas and BCBS South Carolina run it the other way, naming Actemra itself preferred. Check this patient’s payer →
It varies by payer. In CareCost’s corpus, Capital BlueCross renews prior authorization every 12 months, capped at 18 months of therapy for giant cell arteritis, and BCBS Michigan and Centene reauthorize on documented clinical response. Cytokine release syndrome is the exception: BCBS Michigan’s policy treats the course as a one-time approval, with no further authorization provided. Check this patient’s payer →
Data current: payer policies Aug 2026 · reviewed dates come from each payer
Payer medical and specialty-drug policies · prior-authorization criteria · site-of-care policies · clinical-prerequisite criteria. Medicare coverage follows Part B buy-and-bill rules, priced off the ASP-based fee schedule. Every CareCost requirement links back to its source policy.